These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

506 related articles for article (PubMed ID: 27705910)

  • 1. Indoleamine 2,3-dioxygenase regulates anti-tumor immunity in lung cancer by metabolic reprogramming of immune cells in the tumor microenvironment.
    Schafer CC; Wang Y; Hough KP; Sawant A; Grant SC; Thannickal VJ; Zmijewski J; Ponnazhagan S; Deshane JS
    Oncotarget; 2016 Nov; 7(46):75407-75424. PubMed ID: 27705910
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tumor-infiltrating Treg, MDSC, and IDO expression associated with outcomes of neoadjuvant chemotherapy of breast cancer.
    Li F; Zhao Y; Wei L; Li S; Liu J
    Cancer Biol Ther; 2018 Aug; 19(8):695-705. PubMed ID: 29621426
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Indoleamine 2, 3-Dioxygenase Promotes Aryl Hydrocarbon Receptor-Dependent Differentiation Of Regulatory B Cells in Lung Cancer.
    Tousif S; Wang Y; Jackson J; Hough KP; Strenkowski JG; Athar M; Thannickal VJ; McCusker RH; Ponnazhagan S; Deshane JS
    Front Immunol; 2021; 12():747780. PubMed ID: 34867973
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tumor-associated GM-CSF overexpression induces immunoinhibitory molecules via STAT3 in myeloid-suppressor cells infiltrating liver metastases.
    Thorn M; Guha P; Cunetta M; Espat NJ; Miller G; Junghans RP; Katz SC
    Cancer Gene Ther; 2016 Jun; 23(6):188-98. PubMed ID: 27199222
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.
    Holmgaard RB; Zamarin D; Lesokhin A; Merghoub T; Wolchok JD
    EBioMedicine; 2016 Apr; 6():50-58. PubMed ID: 27211548
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CARD9 prevents lung cancer development by suppressing the expansion of myeloid-derived suppressor cells and IDO production.
    Qu J; Liu L; Xu Q; Ren J; Xu Z; Dou H; Shen S; Hou Y; Mou Y; Wang T
    Int J Cancer; 2019 Oct; 145(8):2225-2237. PubMed ID: 31008530
    [TBL] [Abstract][Full Text] [Related]  

  • 7. MDSCs use a complex molecular network to suppress T-cell immunity in a pulmonary model of fungal infection.
    Kaminski VL; Borges BM; Santos BV; Preite NW; Calich VLG; Loures FV
    Front Cell Infect Microbiol; 2024; 14():1392744. PubMed ID: 39035356
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Indoleamine 2,3-dioxygenase-1 involves in CD8
    Zhou Y; Yao L; Ma T; Wang Z; Yin Y; Yang J; Zhang X; Zhang M; Qin G; Ma J; Zhao L; Liang J; Zhang J
    Int Immunopharmacol; 2024 Dec; 142(Pt A):113062. PubMed ID: 39244898
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Indoleamine 2,3-dioxygenase regulates T cell activity through Vav1/Rac pathway.
    Li R; Li H; Sun Q; Liu L; Zhang C; Ren X
    Mol Immunol; 2017 Jan; 81():102-107. PubMed ID: 27930920
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ganoderma lucidum polysaccharide (GLP) enhances antitumor immune response by regulating differentiation and inhibition of MDSCs via a CARD9-NF-κB-IDO pathway.
    Wang Y; Fan X; Wu X
    Biosci Rep; 2020 Jun; 40(6):. PubMed ID: 32530032
    [TBL] [Abstract][Full Text] [Related]  

  • 11. STING Promotes the Growth of Tumors Characterized by Low Antigenicity via IDO Activation.
    Lemos H; Mohamed E; Huang L; Ou R; Pacholczyk G; Arbab AS; Munn D; Mellor AL
    Cancer Res; 2016 Apr; 76(8):2076-81. PubMed ID: 26964621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibiting myeloid-derived suppressor cell trafficking enhances T cell immunotherapy.
    Sun L; Clavijo PE; Robbins Y; Patel P; Friedman J; Greene S; Das R; Silvin C; Van Waes C; Horn LA; Schlom J; Palena C; Maeda D; Zebala J; Allen CT
    JCI Insight; 2019 Apr; 4(7):. PubMed ID: 30944253
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The Combination of MEK Inhibitor With Immunomodulatory Antibodies Targeting Programmed Death 1 and Programmed Death Ligand 1 Results in Prolonged Survival in Kras/p53-Driven Lung Cancer.
    Lee JW; Zhang Y; Eoh KJ; Sharma R; Sanmamed MF; Wu J; Choi J; Park HS; Iwasaki A; Kaftan E; Chen L; Papadimitrakopoulou V; Herbst RS; Koo JS
    J Thorac Oncol; 2019 Jun; 14(6):1046-1060. PubMed ID: 30771521
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic antitumor effect with indoleamine 2,3-dioxygenase inhibition and temozolomide in a murine glioma model.
    Hanihara M; Kawataki T; Oh-Oka K; Mitsuka K; Nakao A; Kinouchi H
    J Neurosurg; 2016 Jun; 124(6):1594-601. PubMed ID: 26636389
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Indoleamine 2,3-dioxygenase increases p53 levels in alloreactive human T cells, and both indoleamine 2,3-dioxygenase and p53 suppress glucose uptake, glycolysis and proliferation.
    Eleftheriadis T; Pissas G; Antoniadi G; Spanoulis A; Liakopoulos V; Stefanidis I
    Int Immunol; 2014 Dec; 26(12):673-84. PubMed ID: 25064493
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Indoleamine 2,3-dioxygenase depletes tryptophan, activates general control non-derepressible 2 kinase and down-regulates key enzymes involved in fatty acid synthesis in primary human CD4+ T cells.
    Eleftheriadis T; Pissas G; Antoniadi G; Liakopoulos V; Stefanidis I
    Immunology; 2015 Oct; 146(2):292-300. PubMed ID: 26147366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of indoleamine 2,3-dioxygenase in acute myeloid leukemia.
    Sobash PT; Kolhe R; Karim NA; Guddati AK; Jillella A; Kota V
    Future Oncol; 2020 Dec; 16(36):3085-3094. PubMed ID: 32976029
    [TBL] [Abstract][Full Text] [Related]  

  • 18. STING agonist and IDO inhibitor combination therapy inhibits tumor progression in murine models of colorectal cancer.
    Shi J; Liu C; Luo S; Cao T; Lin B; Zhou M; Zhang X; Wang S; Zheng T; Li X
    Cell Immunol; 2021 Aug; 366():104384. PubMed ID: 34182334
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tumor-Targeted Gene Silencing IDO Synergizes PTT-Induced Apoptosis and Enhances Anti-tumor Immunity.
    Zhang Y; Feng Y; Huang Y; Wang Y; Qiu L; Liu Y; Peng S; Li R; Kuang N; Shi Q; Shi Y; Chen Y; Joshi R; Wang Z; Yuan K; Min W
    Front Immunol; 2020; 11():968. PubMed ID: 32582152
    [No Abstract]   [Full Text] [Related]  

  • 20. Targeted Deletion of CXCR2 in Myeloid Cells Alters the Tumor Immune Environment to Improve Antitumor Immunity.
    Yang J; Yan C; Vilgelm AE; Chen SC; Ayers GD; Johnson CA; Richmond A
    Cancer Immunol Res; 2021 Feb; 9(2):200-213. PubMed ID: 33177110
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 26.